SARS-CoV-2 can cause its most lethal damage to the lungs, heart and blood vessels. But the nose is usually the first stop in the human body, because that’s where viral particles come into cells that can attack them and remove them to make copies of themselves. From there, a swarm of new viruses can spread to other organs – unless the immune system shuts them down. And it is from the nose that infected people can put out new falling clouds.
So for a vaccine to completely prevent its spread, it had to employ a group of antibodies and SARS-CoV-2 immune cells specifically to circumvent the nasal passages, where they could call any coronaviruses immediately after get in, and before they start the self-reproduction spree. Here’s how the nasal spray versions of flu vaccines work. But that’s not exactly what Pfizer or Moderna images were designed to do. They are designed to create a sparser team of broader immune guards that can initiate a greater response wherever they encounter the virus, giving a person with an infection a better chance of developing full-blown symptoms. bring back. “The goal of these vaccines has always been to prevent hospital admissions and deaths, because they have the greatest impact on public health,” Talaat said.
The good news about Israeli and UK studies is that even with their procedural flaws in terms of distribution, Talaat says, they show that out in the real world, away from the parameters under clinical trial control, that the vaccines actually work to prevent people from becoming seriously ill. In the Israeli report released, vaccines caused a 95 percent drop in hospitals and a 92 percent drop in deaths. And more recent data, with better analysis already beginning to support that.
A study was published Wednesday in the New England Journal of Medicine analyzed 600,000 pairs of vaccinated and unvaccinated Israelis found that two doses of the Pfizer formulated 92 percent protection against serious disease and 87 percent effective in preventing hospitalization . Although the study did not include data on deaths after the second dose, only one stroke lowered mortality rates by 72 percent. So, from a public health perspective, that raises the question of whether the Pfizer vaccine, or any other, stopping viral transmission is a real concern, Talaat said. “If you get enough vaccines in people, you don’t need a vaccine that stops nasal congestion and can be spread,” she says.
But that number is different to answer questions like this: Is it safe to eat inside a restaurant? Or get on a plane? Or hey your grandmothers?
The vaccine you receive is said to be 80 percent effective in preventing viral transmission. That means that if you catch the virus, you may not be very ill or even have a single symptom – but there is still a 20 percent chance that you will pass it on to someone else. And what if the vaccine you receive is only 50 percent effective in preventing transmission? Now it’s a dog flip.
“This is just the kind of gray area where reasonable people could come up with different answers,” Halpern said. “It’s because we don’t all have the same risk tolerance.”
Talaat’s version of this calculus involves experiencing families with her parents (vaccinated) and her sisters (unvaccinated). Since she herself is getting the vaccine, Talaat still wears a mask when she visits her brothers. And she will continue to do so until they get their pictures. But she feels more relaxed around her parents. “If you are in a home or pod with someone who has not been vaccinated, you should be as careful as you can to prevent it spreading, especially if that person is at high risk. ”She says.